Has Wenyin Shi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $119,469 in general payments to Wenyin Shi, MD across 132 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Wenyin Shi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Wenyin Shi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Wenyin Shi, MD

Radiation Oncology · Philadelphia, PANPI 1821178690

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $78,137 of the $119,469 with a category attached, or 65.4%. 15 manufacturers reported payments, led by Novocure Inc. at 46.1% of the total. Reporting peaked in 2023 at $44,410 and has fallen 92.1% since, to $3,530 in 2025. Among radiation oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$119,469in general payments, 2019–2025

Across 132 payments — averaging $905.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novocure Inc.$55K
Novocure GmbH$28K
Siemens Medical Solutions USA, Inc.$12K
Brainlab, Inc.$10K
Varian Medical Systems, Inc.$9K
Sanofi$3K
plus $3K from 9 others

$1,006,946in research payments, 2019–2025

Across 31 payments — averaging $32,482 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novocure GmbH$612K
Novocure Inc.$309K
Regeneron$86K

What the payments were for

Consulting fees$78,13765%
Speaking & faculty fees$7,5006%
Grants$14,81412%
Travel & lodging$13,70511%
Food & beverage$5,3144%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novocure Inc.	52	$55,068
Novocure GmbH	2	$27,500
Siemens Medical Solutions USA, Inc.	22	$12,130
Brainlab, Inc.	26	$9,971
Varian Medical Systems, Inc.	5	$9,258
Sanofi	1	$3,036
Zap Surgical Systems, Inc.	6	$944
Medtronic	3	$595
Telix Pharmaceuticals	4	$289
Icotec Medical Inc.	5	$201
E.r. Squibb & Sons, L.L.C.	1	$150
Elekta, Inc.	2	$132
Merck	1	$115
Ion Beam Applications S.A.	1	$51
Regeneron	1	$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$119,469 in reported general payments places this provider in the 95th percentile of 339 radiation oncology providers in Pennsylvania.

See all radiation oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$112,150

Medicare patients

160

Services billed

1,225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dexamethasone	42	$312
Lorazepam	12	$24

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Philadelphia

Neil TaunkPhiladelphia$203K
Kevin NeadPhiladelphia$50K
Adam DickerPhiladelphia$46K
Tinatin ChabrashviliPhiladelphia$39K
Bryan PukenasPhiladelphia$36K
Sameera KumarPhiladelphia$29K
Joshua MeyerPhiladelphia$25K
Abigail BermanPhiladelphia$25K
Michelle Alonso-BasantaPhiladelphia$23K
Andy MinnPhiladelphia$22K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →